Verrica Pharmaceuticals Inc. (VRCA) EPS Estimated At $-0.25

October 13, 2018 - By Louis Casey

Analysts expect Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) to report $-0.25 EPS on November, 6.After having $-1.04 EPS previously, Verrica Pharmaceuticals Inc.’s analysts see -75.96 % EPS growth. The stock increased 5.60% or $0.74 during the last trading session, reaching $13.95. About 42,510 shares traded. Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company has market cap of $358.47 million. The firm is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It currently has negative earnings. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.

More news for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) were recently published by: Nasdaq.com, which released: “Verrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000® and Russell 3000® Indexes” on September 24, 2018. Seekingalpha.com‘s article titled: “Verrica Pharmaceuticals to join Russell indexes” and published on September 24, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>